A-357300
A-357300 is a reversible and selective MetAP2 inhibitor with IC50s of 0.12 and 57 μM against MetAP2 and MetAP1. A-357300 induces cytostasis by cell cycle arrest at the G1 phase selectively in endothelial cells and in a subset of tumor cells. A-357300 inhibits angiogenesis both in vitro and in vivo and shows potent antitumor efficacy in carcinoma, sarcoma, and neuroblastoma murine models. A-357300 can be used for the studies of neuroblastoma, fibrosarcoma and breast cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 369358-07-6
- 화학식: C15H22ClN3O3S
- 분자량:359.87
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
|
MetAp2 0.12 μM (IC50) |
MetAp1 57 μM (IC50) |
A-357300 (0.1 nM-100 μM, 3 days) exhibits selective antiproliferative activity against endothelial cells and tumor cells with IC50s of 0.1-2 μM, but not in human primary cells[1].
A-357300 (10 μM, 3 days) induces cytostasis by cell cycle arrest at the G1 phase in HMVECs or HT-1080 cells[1].
A-357300 (0-10 μM, 1 day) reduces the concentration of cyclin A, while keeping the concentration of cyclin D1 unchanged in HMVECs[1].
A-357300 (0.08-2 μM, 3 days) completely blocks the formation of the lumen at a concentration of 0.4 μM in HMVECs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HMVECs and HT-1080 cells
-
Concentration:10 μM
-
Incubation Time:3 days
-
Result:Showed G1 phase arrest, with no accumulation of sub-G1 phase cells.
-
Cell Line:HMVECs
-
Concentration:0, 0.001, 0.01, 0.1, 1 and 10 μM
-
Incubation Time:24 h
-
Result:Reduced the concentration of cyclin A, while keeping the concentration of cyclin D1 unchanged.
A-357300 (8-100 mg/kg, s.c., once every other day or twice daily for 14-24 days) inhibits the growth of neuroblastoma, fibrosarcoma and breast cancer in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Corneal angiogenesis model established in CF1 mice[1]
-
Dosage:25, 75 and 100 mg/kg
-
Administration:Subcutaneous injection (s.c.), twice daily for 7 days
-
Result:Inhibited growth factor-induced cornea neovascularization in a dose-dependent manner against VEGF, and against bFGF.
-
Animal Model:CHP-134 neuroblastoma xenograft model established in mice[1]
-
Dosage:100 mg/kg
-
Administration:Subcutaneous injection (s.c.), twice daily for 24 days
-
Result:Significantly suppressed growth of this established tumor xenograft with a T/C of 0.185 on day 24 after the initiation of treatment.
-
Animal Model:HT-1080 fibrosarcoma xenograft model established in SCID-beige mice[1]
-
Dosage:15, 30, 60 and 100 mg/kg
-
Administration:Subcutaneous injection (s.c.), twice daily for 14-16 days
-
Result:Inhibited tumor growth in a dose-dependent manner and no overt signs of toxicity were observed.
-
Animal Model:MDA-435-LM breast cancer xenograft model established in SCID mice[1]
-
Dosage:8, 16, 20 mg/kg (group 1); 50 and 100 mg/kg (group 2)
-
Administration:Subcutaneous injection (s.c.), once every other day (group 1) or twice daily (group 2) for 20 days
-
Result:Exhibited better efficacy in group 2 than group 1.
Chemical Information
-
CAS No. 369358-07-6
-
분자량 359.87
-
화학식 C15H22ClN3O3S
-
SMILES
CC(C)SCC[C@@H](N)[C@H](O)C(NNC(C1=CC(Cl)=CC=C1)=O)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
A-357300 Related Classifications
HY-116861 Related Classifications
Powered by Bioz